Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 193

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia

Open access
Williams, Richard T., Roussel, Martine F., Sherr, Charles J.·2006·Proceedings of the National Academy of Sciences

Abstract

Mouse bone marrow cells transduced with retroviral vectors encoding either of two oncogenic Bcr-Abl isoforms (p210 Bcr-Abl and p185 Bcr-Abl ) induce B cell lympholeukemias when transplanted into lethally irradiated mice. If the activity of the Arf tumor suppressor is compromised, these donor cells initiate a much more highly aggressive and rapidly fatal disease. When mouse bone marrow cells expressing Bcr-Abl are placed in short-term cultures selectively designed to support the outgrowth of pre-B cells, only those lacking one or two Arf alleles can initiate lympholeukemias when inoculated into immunocompetent, syngeneic recipient mice. Although the ABL kinase inhibitor imatinib mesylate (Gleevec) provides highly effective treatment for BCR-ABL-positive chronic myelogenous leukemia, it has proven far less efficacious in the treatment of BCR-ABL-positive acute lymphoblastic leukemias (ALLs), many of which sustain deletions of the INK4A-ARF ( CDKN2A ) tumor suppressor locus. Mice receiving Arf −/− or Arf +/− p210 Bcr-Abl -positive pre-B cells do not achieve remission when maintained on high doses of oral imatinib therapy and rapidly succumb to lympholeukemia. Although cells expressing the Bcr-Abl kinase can proliferate in the absence of IL-7, they remain responsive to this cytokine, which can reduce their sensitivity to imatinib. Treatment of Arf −/− , p210 Bcr-Abl -positive pre-B cells with imatinib together with an inhibitor of JAK kinases abrogates this resistance, suggesting that this combination may prove beneficial in the treatment of BCR-ABL-positive acute lymphoblastic leukemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0602030103

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 29

  1. P. Nowell, D. Hungerford J. Natl. Cancer Inst 25, 85–109 (1960).
  2. 10.1016/0092-8674(84)90077-1 · DOI · Paper page
  3. 10.1126/science.3541203 · DOI · Paper page
  4. 10.1038/325635a0 · DOI
  5. 10.1038/283826a0 · DOI · Paper page
  6. 10.1182/blood-2004-08-3097 · DOI · Paper page
  7. 10.1016/S1535-6108(02)00096-X · DOI · Paper page
  8. 10.1126/science.1099480 · DOI · Paper page
  9. N. P. Shah Hematology: The American Society of Hematology Education Program Book (Am. Soc. Hematol., Washington, DC), pp. 183–187 (2005).
  10. 10.1200/JCO.2005.05.047 · DOI · Paper page
  11. 10.1038/sj.leu.2403324 · DOI
  12. 10.1038/sj.leu.2403714 · doi:10.1038/sj.leu.2403714
  13. 10.1101/gad.12.15.2434 · DOI · Paper page
  14. 10.1038/25870 · DOI · Paper page
  15. 10.1073/pnas.95.22.13194 · DOI
  16. 10.1016/j.cell.2004.08.005 · DOI · Paper page
  17. 10.1101/gad.13.20.2670 · DOI · Paper page
  18. 10.1101/gad.13.20.2678 · DOI · Paper page
  19. 10.1016/0076-6879(87)50085-4 · DOI
  20. 10.1073/pnas.171217498 · DOI
  21. 10.1073/pnas.84.18.6558 · DOI
  22. 10.1089/hyb.2004.23.293 · DOI
  23. 10.1038/ng1343 · DOI · Paper page
  24. 10.1182/blood.V98.9.2808 · DOI
  25. N. Jena, M. Deng, E. Sicinska, P. Sicinski, G. Q. Daley Cancer Res 62, 535–541 (2002).
  26. 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
  27. 10.1073/pnas.052484199 · DOI
  28. 10.1089/hyb.1994.13.37 · DOI
  29. 10.4161/cc.4.11.2174 · DOI

Cited by

See all 193

Metadata

Authors
Williams, R. T., Roussel, M. F., & Sherr, C. J.
Venue
Proceedings of the National Academy of Sciences
Published
2006-04-25
Volume
103
Issue
17
Pages
6688-6693
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2147270774
Cited by
193
References
6
FWCI
7.20
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1073/pnas.0602030103
The paper
Williams, R. T., Roussel, M. F., & Sherr, C. J. (2006). Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0602030103

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.